Insulin-sensitising agents: Beyond thiazolidinediones

Expert Opinion on Emerging Drugs

Volumn 7, Issue 1, 2002, Pages 165-174

  Perry, Colin G ^a   Petrie, John R ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Adiponectin; Insulin resistance; Leptin; Peroxisome proliferator activated receptor; Resistin; Thiazolidinediones

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; CARBENOXOLONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYBRID PROTEIN; INOSITOL DERIVATIVE; INSULIN; LEPTIN; NEUTRALIZING ANTIBODY; NORASTERRIQUINONE B1; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITIDE; PRASTERONE; TOPIRAMATE; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR RECOMBINANT FUSION PROTEIN; UNCLASSIFIED DRUG;

ADIPOCYTE; CLINICAL TRIAL; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; ENZYME ACTIVATION; HORMONE ACTION; HUMAN; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW;

EID: 0036078284     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.7.1.165     Document Type: Review

References (63)

1. Diabetes. Exploding type II
2. The rising global burden of diabetes and its complications: Estimates and projections to the year 2010
3. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33)
4. Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34)
5. Role of AMP-activated protein kinase in mechanism of merformin action
6. Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance
7. Insulin signalling and the regulation of glucose and lipid metabolism
8. Activation of mitogen-activated protein kinase and phosphatidylinositol 3′-kinase is not sufficient for the hormonal stimulation of glucose uptake, lipogenesis, or glycogen synthesis in 3T3-L1 adipocytes
9. Evidence for defects in the trafficking and translocation of GLUT4 glucose transporters in skeletal muscle as a cause of human insulin resistance
10. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance
11. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver
12. The hormone resistin links obesity to diabetes
13. Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade
14. Tumor necrosis factor (TNF)-alpha inhibits insulin signaling through stimulation of the p55 TNF receptor and activation of sphingomyelinase
15. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity
16. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction
17. Orphan nuclear receptors: From gene to function
18. Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists
19. Peroxisome proliferator-activated receptors, orphans with ligands and functions
20. Thiazolidinediones and insulin resistance: Peroxisome proliferatoractivated receptor gamma activation stimulates expression of the CAP gene
21. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene
22. Enhancement of adipocyte differentiation by an insulin-sensitizing agent
23. 15-Deoxy-deka 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma
24. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay
25. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity
26. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of Type 2 diabetes
27. Improved insulin- sesitivity in mice heterozygous for PPAR-gamma deficiency
28. Inhibition of RXR and PPARgamma ameliorates diet-induced obesity and Type 2 diabetes
29. Skeletal muscle triglyceride. An aspect of regional adiposity and insulin resistance
30. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation
31. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisom e proliferator-activated receptors alpha and delta
32. Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids
33. In vitro studies on the action of CS-045, a new antidiabetic agent
34. Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosightazone
35. The glucose fatty acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus
36. Adipose expression of tumor necrosis factor-alpha: Direct role in obesity-linked insulin resistance
37. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase
38. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance
39. Effects of an engineered human and-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM
40. No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insuhn-resistant patients
41. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity
42. Leptin: The tale of an obesity gene
43. Congenital leptin deficiency is associated with severe early-onset obesity in humans
44. Weight-reducing effects of the plasma protein encoded by the obese gene
45. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase
46. Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11 beta-hydroxysteroid dehydrogenase Type 1 null mice
47. A transgenic model of visceral obesity and the metabolic syndrome
48. Carbenoxolone increases hepatic insulin sensitivity in man: A novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation
49. Opposing actions of dehydroepiandrosterone and testosterone on insulin sensitivity. In vivo and in vitro studies of hyperandrogenic females
50. Dehydroepiandrosterone decreases serum tumor necrosis factor-alpha and restores insulin sensitivity: Independent effect from secondary weight reduction in genetically obese Zucker fatty rats
51. Dhea protects against visceral obesity and muscle insulin resistance in rats fed a high-fat diet
52. Dehydroepiandrosterone sulfate and beta-cell function: Enhanced glucose-induced insulin secretion and altered gene expression in rodent pancreatic beta-cells
53. Metabolic effects of dehydroepiandrosterone replacement therapy in postmenopausal women
54. Ovulatory and metabolic effects of D-chiroinositol in the polycystic ovary syndrome
55. Effect of pinitol treatment on insulin action in subjects with insulin resistance
56. Effect of topiramate on body weight and body composition of osborne-mendel rats fed a high-fat diet: Alterations in hormones, neuropeptide, and uncoupling-protein mRNAs
57. Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats
58. Long-term effects of topiramate on bipolar mood instability, weight change and glycemic control: A case-series
59. Discovery of a small molecule insulin mimetic with antidiabetic activity in mice
60. A novel small molecule that directly sensitizes the insulin receptor in vitro and in vivo
61. Small molecule insulin receptor activators potentiate insulin action in insulin-resistant cells
62. Prevention of Type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance
63. Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin